Breakfast Technical Briefing on Biotech Stocks -- Pacific Biosciences of California, Puma Biotechnology, PDL BioPharma, and Progenics Pharma

Thursday, August 3, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, August 3, 2017 /PRNewswire/ --

If you want a Stock Review on PACB, PBYI, PDLI, or PGNX then come over to and sign up for your free customized report today. has issued research reports on Pacific Biosciences of California Inc. (NASDAQ: PACB), Puma Biotechnology Inc. (NASDAQ: PBYI), PDL BioPharma
Inc. (NASDAQ: PDLI), and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). According to a Zacks report, expectations are high that the Biotech sector will witness an increase in M&As as the year progresses; potential tax reform and cash repatriation are expected to lead to a boost in this area. However, not many deals have been announced this year - a key reason could be a "wait and watch" approach regarding the drug pricing situation as well as tax reforms. Daily Stock Tracker published free research reports on these stocks today at:

Pacific Biosciences of California 

Menlo Park, California headquartered Pacific Biosciences of California Inc.'s shares declined 0.62%, closing Wednesday's trading session at $3.20. The stock recorded a trading volume of 569,683 shares. The Company's shares are trading 7.42% below their 50-day moving average. Additionally, shares of Pacific Biosciences of California, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have a Relative Strength Index (RSI) of 40.71. See our free and comprehensive research report on PACB at:

Puma Biotechnology 

Los Angeles, California headquartered Puma Biotechnology Inc.'s stock finished the day 0.83% lower at $89.20 with a total trading volume of 890,584 shares. The Company's shares have advanced 1.54% in the last one month, 140.76% in the previous three months, and 190.55% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.44% and 80.39%, respectively. Additionally, shares of Puma Biotechnology, which focuses on the development and commercialization of products to improve cancer care, have an RSI of 46.22.  

On July 10th, 2017, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock, with a target price of $115 per share.

On July 17th, 2017, Puma Biotechnology announced that the US Food and Drug Administration has approved NERLYNX™ (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. The Company expects neratinib to become commercially available in September 2017 and to be marketed as NERLYNX. PBYI free research report is just a click away at:

PDL BioPharma 

On Wednesday, shares in Incline Village, Nevada headquartered PDL BioPharma Inc. recorded a trading volume of 2.11 million shares, which was above their three months average volume of 1.49 million shares. The stock declined 0.89%, ending the day at $2.22. The Company's shares have advanced 2.78% in the previous three months and 4.72% on an YTD basis. The stock is trading below its 200-day moving average by 7.22%. Furthermore, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the US, Europe, and internationally, have an RSI of 34.25.  

On July 31st, 2017, PDL BioPharma announced that it will release its Q2 financial results for the period ended June 30th, 2017, on August 03rd, 2017, after market close. Management will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results. The live and subsequently archived webcast of the conference call may be accessed on the Company's website. Sign up for your complimentary report on PDLI at:

Progenics Pharma 

Shares in New York-based Progenics Pharmaceuticals Inc. ended yesterday's session 3.32% lower at $5.83. The stock recorded a trading volume of 647,521 shares. The Company's shares are trading 14.18% below their 50-day moving average. Moreover, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 24.98.  

On July 26th, 2017, Progenics Pharma announced that it will host a conference call and webcast to review the second quarter ended June 30th, 2017, financial results on August 09th, 2017, at 8:30 a.m. ET. The live webcast will be available under the Media Center section of the Company's website. Register for free on and download the latest research report on PGNX at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store